Lifog (Latanoprost)

Latanoprost binds to prostaglandin F (FP) receptors in the eye, triggering remodeling of the extracellular matrix in the ciliary body. This increases uveoscleral outflow of aqueous humor, which lowers intra‑ocular pressure and reduces the risk of glaucomatous optic‑nerve injury.

The prescribed dose of Lifog is determined by the treating ophthalmologist. In clinical practice the medication is typically instilled as one drop in the affected eye(s) once daily in the evening, but the exact regimen should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and to consider possible exposure to a nursing infant before prescribing to breastfeeding mothers.

To order Lifog, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lifog (latanoprost) belongs to the prostaglandin analog class, which typically offers once‑daily dosing and a strong pressure‑lowering effect. Compared with beta‑blocker drops such as timolol, latanoprost often provides greater IOP reduction and a different side‑effect profile, including cosmetic changes like iris darkening.

Lifog should be stored at room temperature, below 25 °C, in its original container. Protect the bottle from light and moisture, and keep the cap tightly closed when not in use to maintain sterility and potency.

Lifog is applied as an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place one drop into the conjunctival sac of the prescribed eye(s). Close the eye gently for a few seconds and avoid blinking excessively.

Serious adverse events, although rare, include severe ocular inflammation such as uveitis or iritis, paradoxical increase in intra‑ocular pressure, and macular edema that can affect central vision. Prompt medical evaluation is required if any of these symptoms arise.

Lifog is contraindicated in patients with known hypersensitivity to latanoprost or any component of the formulation. It should also be avoided in individuals with active ocular infections, recent ocular surgery (unless cleared by a physician), and in pregnant or nursing women unless the benefit outweighs potential risks.